Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Boca Raton, FL
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Jacksonville, FL
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Indianapolis, IN
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Sioux City, IA
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Sioux City, IA
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Kansas City, KA
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Kansas City, KA
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative site
mi
from
Boston, MA
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Ann Arbor, MI
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigator Site
mi
from
Minneapolis, MN
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigator Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigator Site
mi
from
Albuquerque, NM
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigator Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Santa Fe, NM
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis
mi
from
New York, NY
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Chapel Hill, NC
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Philadelphia, PA
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis
mi
from
Pittsburgh, PA
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Nashville, TN
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative site
mi
from
Dallas, TX
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Houston, TX
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Tyler, TX
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Tyler, TX
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Seattle, WA
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Yakima, WA
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Yakima, WA
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
North Sydney,
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
North Sydney,
Click here to add this to my saved trials
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated:  4/27/2018
Novartis Investigative Site
mi
from
Saint Louis, MO
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Status: Enrolling
Updated: 4/27/2018
Novartis Investigative Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Microsurgical Breast Reconstruction & VTE
Microsurgical Breast Reconstruction - Identifying Procedure-Specific Risk Factors for Venous Thromboembolism
Status: Enrolling
Updated:  4/29/2018
Stanford Univ Med Ctr
mi
from
Stanford, CA
Microsurgical Breast Reconstruction & VTE
Microsurgical Breast Reconstruction - Identifying Procedure-Specific Risk Factors for Venous Thromboembolism
Status: Enrolling
Updated: 4/29/2018
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
A Phase 2 Study of [18F] Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer
Status: Enrolling
Updated:  4/30/2018
University of Washington Medical Center
mi
from
Seattle, WA
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
A Phase 2 Study of [18F] Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer
Status: Enrolling
Updated: 4/30/2018
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer
A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer
Status: Enrolling
Updated:  4/30/2018
University of Chicago
mi
from
Chicago, IL
A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer
A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer
Status: Enrolling
Updated: 4/30/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Preoperative Massage in Breast Surgery Patients
Utility of Preoperative Massage in Breast Surgery Patients
Status: Enrolling
Updated:  4/30/2018
Vassar Brothers Medical Center
mi
from
Poughkeepsie, NY
Preoperative Massage in Breast Surgery Patients
Utility of Preoperative Massage in Breast Surgery Patients
Status: Enrolling
Updated: 4/30/2018
Vassar Brothers Medical Center
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated:  4/30/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated: 4/30/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated:  4/30/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated: 4/30/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated:  4/30/2018
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated: 4/30/2018
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
Click here to add this to my saved trials
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated:  4/30/2018
Univ of Minnesota
mi
from
Minneapolis, MN
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated: 4/30/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated:  4/30/2018
University Hospital of Cleveland, Case Medical Center, Seidman Cancer Center
mi
from
Cleveland, OH
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated: 4/30/2018
University Hospital of Cleveland, Case Medical Center, Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated:  4/30/2018
Institut Jules Bordet
mi
from
Bruxelles,
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated: 4/30/2018
Institut Jules Bordet
mi
from
Bruxelles,
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Patients With Locally Advanced or Stage IV HER2 Positive Breast Cancer
Status: Enrolling
Updated:  5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Patients With Locally Advanced or Stage IV HER2 Positive Breast Cancer
Status: Enrolling
Updated: 5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation
A Feasibility Study of the Effects of a Directed Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation
Status: Enrolling
Updated:  5/1/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation
A Feasibility Study of the Effects of a Directed Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation
Status: Enrolling
Updated: 5/1/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Phase I-II Study of HER2 Vaccination With Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients
Status: Enrolling
Updated:  5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Phase I-II Study of HER2 Vaccination With Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients
Status: Enrolling
Updated: 5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Quantitative Subharmonic Breast Imaging
Quantitative Subharmonic Breast Imaging
Status: Enrolling
Updated:  5/1/2018
The University of California, San Diego
mi
from
La Jolla, CA
Quantitative Subharmonic Breast Imaging
Quantitative Subharmonic Breast Imaging
Status: Enrolling
Updated: 5/1/2018
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Quantitative Subharmonic Breast Imaging
Quantitative Subharmonic Breast Imaging
Status: Enrolling
Updated:  5/1/2018
Thomas Jefferson University, Dept of Radiology
mi
from
Philadelphia, PA
Quantitative Subharmonic Breast Imaging
Quantitative Subharmonic Breast Imaging
Status: Enrolling
Updated: 5/1/2018
Thomas Jefferson University, Dept of Radiology
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers
Navigated Early Survivorship Transition in Improving Survivorship Care Planning in Patients With Newly Diagnosed Cancer and Their Caregivers (NEST)
Status: Enrolling
Updated:  5/1/2018
Meharry Medical College
mi
from
Nashville, TN
Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers
Navigated Early Survivorship Transition in Improving Survivorship Care Planning in Patients With Newly Diagnosed Cancer and Their Caregivers (NEST)
Status: Enrolling
Updated: 5/1/2018
Meharry Medical College
mi
from
Nashville, TN
Click here to add this to my saved trials
Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers
Navigated Early Survivorship Transition in Improving Survivorship Care Planning in Patients With Newly Diagnosed Cancer and Their Caregivers (NEST)
Status: Enrolling
Updated:  5/1/2018
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers
Navigated Early Survivorship Transition in Improving Survivorship Care Planning in Patients With Newly Diagnosed Cancer and Their Caregivers (NEST)
Status: Enrolling
Updated: 5/1/2018
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors
Status: Enrolling
Updated:  5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors
Status: Enrolling
Updated: 5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer
Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer
Status: Enrolling
Updated:  5/1/2018
UCSF Breast Care Center
mi
from
San Francisco, CA
Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer
Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer
Status: Enrolling
Updated: 5/1/2018
UCSF Breast Care Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Five Sessions Intervention to Facilitate Adaptation to Breast Cancer
Five Sessions Intervention to Facilitate Adaptation to Breast Cancer
Status: Enrolling
Updated:  5/1/2018
Department of Psychology
mi
from
Coral Gables, FL
Five Sessions Intervention to Facilitate Adaptation to Breast Cancer
Five Sessions Intervention to Facilitate Adaptation to Breast Cancer
Status: Enrolling
Updated: 5/1/2018
Department of Psychology
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated:  5/2/2018
Lincoln Hospital and Mental Health Center
mi
from
Bronx, NY
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated: 5/2/2018
Lincoln Hospital and Mental Health Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated:  5/2/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated: 5/2/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated:  5/2/2018
Ralph Lauren Center for Cancer Care and Prevention
mi
from
New York, NY
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated: 5/2/2018
Ralph Lauren Center for Cancer Care and Prevention
mi
from
New York, NY
Click here to add this to my saved trials
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated:  5/2/2018
Lutheran Medical Center
mi
from
Brooklyn, NY
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Status: Enrolling
Updated: 5/2/2018
Lutheran Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Effects of Yoga in Breast Cancer Patients
Biobehavioral Effects of Yoga During Breast Cancer Treatment
Status: Enrolling
Updated:  5/2/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Effects of Yoga in Breast Cancer Patients
Biobehavioral Effects of Yoga During Breast Cancer Treatment
Status: Enrolling
Updated: 5/2/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials